The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 36.00, with a high estimate of 47.00 and a low estimate of 21.00. The median estimate represents a +89.57% increase from the last price of 18.99.
The current consensus among 8 polled investment analysts is to Buy stock in Cara Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.56
Reporting Date May 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.